Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$2.6 million.

  • Oncology Institute's Net Cash Flow fell 12399.34% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.9 million, marking a year-over-year decrease of 20031.71%. This contributed to the annual value of $16.2 million for FY2024, which is 1692.68% down from last year.
  • Per Oncology Institute's latest filing, its Net Cash Flow stood at -$2.6 million for Q3 2025, which was down 12399.34% from -$9.4 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Net Cash Flow registered a high of $103.6 million during Q4 2021, and its lowest value of -$47.4 million during Q4 2022.
  • In the last 5 years, Oncology Institute's Net Cash Flow had a median value of -$1.4 million in 2023 and averaged $1.1 million.
  • Within the past 5 years, the most significant YoY rise in Oncology Institute's Net Cash Flow was 391957.94% (2021), while the steepest drop was 337901.78% (2021).
  • Over the past 5 years, Oncology Institute's Net Cash Flow (Quarter) stood at $103.6 million in 2021, then plummeted by 145.75% to -$47.4 million in 2022, then surged by 112.56% to $6.0 million in 2023, then crashed by 65.04% to $2.1 million in 2024, then tumbled by 226.57% to -$2.6 million in 2025.
  • Its last three reported values are -$2.6 million in Q3 2025, -$9.4 million for Q2 2025, and -$9.9 million during Q1 2025.